Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof
AssigneeBeecham Group Limited
InventorsJeffery H. Robinson, Ian Dodd
Life of this patent
Estimating the term…
Abstract
A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.
Claims10
A pharmaceutical composition for treating thrombotic diseases, which comprises an effective amount of a fibrinolytically active hybrid protein in combination with a pharmaceutically acceptable carrier, wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain, said hybrid protein having a catalytic site essential for catalytic activity.
A pharmaceutical composition for treating thrombotic diseases, which comprise an effective amount of a fibrinolytically active hybrid protein in combination with a pharmaceutically acceptable carrier wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain and has a catalytic site essential for catalytic activity blocked by a removable blocking group.
A method of treating a patient suffering from a thrombotic disease, which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active hybrid protein comprising plasmin A-chain covalently linked to tissue plasminogen activator B-chain, said hybrid protein having a catalytic site essential for catalytic activity.
A method of treating a patient suffering from a thrombotic disease, which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active hybrid protein, wherein said hybrid protein comprises plasmin A-chain covalently linked to tissue plasminogen activator B-chain and which has a catalytic site essential for catalytic activity blocked by a removable blocking group.
Dependencies are inferred from the claim text.